BioLab Holdings
Open enrollment with a later-stage pipeline tilt
According to ClinicalTrials.gov-derived indexes, BioLab Holdings sits in the upper quartile of US sponsors by registered trial count (#2,913 of 15,742 sponsors by registered trial count).
BioLab Holdings: 4 sponsored US clinical trials, 3 recruiting.
BioLab Holdings sponsors 4 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting. 2 of these trials are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Venous Leg Ulcer, with 3 trials.
Upper-quartile sponsor footprint
BioLab Holdings sits in the upper quartile of the sponsor corpus (#2,913 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
4 total, page 1 of 1
A Multicenter, Prospective, Controlled Modified Multi-Platform Trial Assessing the Efficacy of Human Placental Membrane Products and Standard of Care in the Management of Nonhealing Diabetic Foot Ulcers and Venous Leg Ulcers.
NCT07364630
Trial Assessing the Efficacy of Human Placental Membrane Products and Standard of Care Versus Standard of Care Alone in the Management of Nonhealing Diabetic Foot Ulcers and Venous Leg Ulcers
NCT07089602
Human Amniotic Membrane On Venous Leg Ulcers In an Elderly Population
NCT06544564
A Real World Data Collection OF Human Amniotic Membrane(s) ON Diabetic Foot Ulcers, Venous LEG Ulcers, Pressure Ulcers AND Post Operative Wounds
NCT07078968
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 4 | 2 |
Therapeutic Areas
Where BioLab Holdings enrollment is open (later-stage tilt)
3 recruiting of 4 indexed (75% open).
Phase mix: 2 late (III/IV) vs 0 early (I/II) (later-stage heavy).
Top condition: Venous Leg Ulcer (3 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
BioLab Holdings: open-pipeline peers nationwide
Peers matched on 4 registered trials and 75% open enrollment, not the therapeutic-area sidebar.
BioLab Holdings sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 4 trials (± recruiting share)
- 4D pharma · 4 trials · 0% recruiting
- 60 Degrees Pharmaceuticals · 4 trials · 50% recruiting
- A2 Biotherapeutics · 4 trials · 75% recruiting
- Abdul Latif Jameel Poverty Action Lab · 4 trials · 25% recruiting
Sponsors near 75% open enrollment (± trial volume)
- Acepodia Biotech · 75% recruiting · 4 trials
- American Laboratory Products Company · 75% recruiting · 4 trials
- Amryt Pharma · 75% recruiting · 4 trials
- Amydis · 75% recruiting · 4 trials
Related
What to do with this BioLab Holdings page
4 registered trials is a research-attention snapshot, not an endorsement of BioLab Holdings or any single study.
- 3 of BioLab Holdings's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Venous Leg Ulcer is the condition BioLab Holdings studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Venous Leg Ulcer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
BioLab Holdings pipeline card: 4 registered trials from official public datasets.Report a data error.